Hereditary hemochromatosis: Perspectives of public health, medical genetics, and primary care

Genetics in Medicine

Volumn 5, Issue 1, 2003, Pages 1-8

  Imperatore, Giuseppina ^a,d   Pinsky, Linda E ^b   Motulsky, Arno ^b   Reyes, Michele ^a   Bradley, Linda A ^c   Burke, Wylie ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Clinigene Laboratories   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Gene; Genetics; Hereditary hemochromatosis; HFE; Iron overload; Screening

Indexed keywords

HFE PROTEIN; IRON; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULTHOOD; ARTHRITIS; CARDIOMYOPATHY; DIABETES MELLITUS; GENE MUTATION; GENOTYPE; HEMOCHROMATOSIS; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER CIRRHOSIS; MEDICAL GENETICS; PHENOTYPE; PHLEBOTOMY; PRIMARY MEDICAL CARE; PUBLIC HEALTH; REVIEW; SCREENING; GENETIC SCREENING; GENETICS; PRIMARY HEALTH CARE;

GENETIC SCREENING; GENETICS, MEDICAL; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON OVERLOAD; MEMBRANE PROTEINS; PRIMARY HEALTH CARE; PUBLIC HEALTH;

EID: 0042306380     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/00125817-200301000-00001     Document Type: Review

References (64)

1. Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997;92:784-789.
2. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
3. Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N, Adams PC et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998;280:172-178.
4. Haddow JE, Bradley LA. Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. BMJ 1999;319:531-532.
5. Cogswell ME, McDonnell SM, Khoury MJ, Franks AL, Burke W, Brittenham G. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Meet 1998;129:971-979.
6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
7. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001;154:193-206.
8. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2000;2:271-277.
9. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
10. Gordeuk V, Mukiibi J, Hasstedt SJ, Samowitz W, Edwards CQ, West G et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med 1992;326:95-100.
11. Bloom PD, Burstien GR, Gorduek VR. Iron overload in African Americans. In: Barton JC, Edwards CQ, editors. Hemochromatosis. New York: Cambridge University Press, 2000:475-484.
12. Barton JC, Edwards CQ, Bertoli LF, Shroyer TW, Hudson SL. Iron overload in African Americans. Am J Med 1995;99:616-623.
13. Gangaidzo IT, Moyo VM, Saungweme T, Khumalo H, Charakupa RM, Gomo ZA et al. Iron overload in urban Africans in the 1990s. Gut 1999;45:278-283.
14. Looker AC, Johnson CL. Prevalence of elevated serum transferrin saturation in adults in the United States. Ann Intern Med 1998;129:940-945.
15. Lindmark B, Eriksson S. Regional differences in the idiopathic hemochromatosis gene frequency in Sweden. Acta Med Stand 1985;218:299-304.
16. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-1362.
17. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990;74:525-530.
18. Smith BN, Kantrowitz W, Grace ND, Greenberg MS, Patton TJ, Ookubo R et al. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is Celtic origin a risk factor? Hepatology 1997;25:1439-1446.
19. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins C et al. Prevalence of hereditary hemochromatosis in 16,031 primary care patients. Ann Intern Med 1998;129:954-961.
20. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998;43:830-836.
21. McDonnell SM, Hover A, Gloe D, Ou CY, Cogswell ME, Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999;107:30-37.
22. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995;98: 464-468.
23. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-624.
24. Burke W, Reyes M, Imperatore G. Hereditary hemochromatosis: a realistic approach to prevention of iron overload disease in the population. Best Pract Res Clin Haematol 2002;15:315-328.
25. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen 1996;3:178-184.
26. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
27. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997;127:105-110.
28. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724.
29. MacSween RN, Scott AR. Hepatic cirrhosis: a clinico-pathological review of 520 cases. J Clin Pathol 1973;26:936-942.
30. MacDonald R. Hemochromatosis and cirrhosis in different geographic areas. Am J Med Sci 1965;249:36-46.
31. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis- associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-953.
32. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-15.
33. Pietrangelo A, Montosi G, Totaro A, Garuti C, Conte D, Cassanelli S et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999;341:725-732.
34. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619-623.
35. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001;28:213-214.
36. Roetto A, Totaro A, Cazzola M, Cicilano M, Bosio S, D'Ascola G et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999;64:1388-1393.
37. Monaghan KG, Rybicki BA, Shurafa M, Feldman GL. Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans. Am J Hematol 1998;58:213-217.
38. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
39. De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G et al. Natural history of juvenile haemochromatosis. Br J Haematol 2002;117:973-979.
40. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-2222.
41. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-337.
42. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-1535.
43. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med 1998;129:925-931.
44. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218.
45. Willis G, Wimperis JZ, Smith KC, Fellows IW, Jennings BA. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999;354:221-222.
46. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-1115.
47. US Preventive Services Task Force. Guide to clinical preventive services, 2nd ed. Baltimore: Williams & Wilkins, 1996.
48. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995;57:1233-1241.
49. Denayer L, Welkenhuysen M, Evers-Kiebooms G, Cassiman JJ, Van den Berghe H. Risk perception after CF carrier testing and impact of the test result on reproductive decision making. Am J Med Genet 1997;69:422-428.
50. Axworthy D, Brock DJ, Bobrow M, Marteau TM. Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. UK Cystic Fibrosis Follow-up Study Group. Lancet 1996;347:1443-1446.
51. Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001;5:107-110.
52. Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998;128:370-373.
53. Kowdley KV, Hassanein T, Kaur S, Farrell FJ, Van Thiel DH, Keeffe EB et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transpl Surg 1995;1:237-241.
54. Emery J, Rose P. Hereditary haemochromatosis: never seen a case? Br J Gen Pract 2001;51:347-348.
55. Seamark CJ, Hutchinson M. Controversy in primary care: should asymptomatic haemochromatosis be treated? BMJ 2000;320:1314-1317.
56. Welch HG, Burke W. Uncertainties in genetic testing for chronic disease. JAMA 1998;280:1525-1527.
57. Phelps G, Chapman I, Hall P, Braund W, Mackinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet 1989;2:233-234.
58. Singh BM, Grunewald RA, Press M, Muller BR, Wise PH. Prevalence of haemochromatosis amongst patients with diabetes mellitus. Diabet Med 1992;9:730-731.
59. O'Brien T, Barrett B, Murray DM, Dinneen S, O'Sullivan DJ. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care 1990; 13:532-534.
60. Kwan T, Leber B, Ahuja S, Carter R, Gerstein HC. Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med 1998;21:251-257.
61. Braun J, Donner H, Plock K, Rau H, Usadel KH, Badenhoop K. Hereditary haemochromatosis mutations (HFE) in patients with type II diabetes mellitus. Diabetobgia 1998;41:983-984.
62. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M et al. Prevalence of hereditary haemochromatosis in late-onset type I diabetes mellitus: a retrospective study. Lancet 2001;358:1405-1409.
63. Griffiths W, Cox T. Haemochromatosis: novel gene discovery and the molecular pathophysiology of iron metabolism. Hum Mol Genet 2000;9:2377-2382.
64. Lee PL, Gelbart T, West C, Halloran C, Felitti V, Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis 2001;27:783-802.